Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer

Devery,Aoife  M.; Wadekar,Rekha; Bokobza,Sivan  M.; Weber,Anika  M.; Jiang,Yanyan; Ryan,Anderson  J.

doi:10.3892/ijo.2015.3082

Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer

Authors:
- Aoife M. Devery
- Rekha Wadekar
- Sivan M. Bokobza
- Anika M. Weber
- Yanyan Jiang
- Anderson J. Ryan
View Affiliations

Affiliations: CRUK and MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Headington, Oxford OX3 7DQ, UK
Published online on: July 14, 2015 https://doi.org/10.3892/ijo.2015.3082
Pages: 849-856
Copyright: © Devery et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF) is a key stimulator of physiological and pathological angiogenesis. VEGF signals primarily through VEGF receptor 2 (VEGFR2), a receptor tyrosine kinase whose expression is found predominantly on endothelial cells. The purpose of this study was to determine the role of VEGFR2 expression in NSCLC cells. NSCLC cells and tissue sections were stained for VEGFR2 expression by immunohistochemistry (IHC). Immunoblotting and ELISA were used to determine the activation and inhibition of VEGFR2 and its downstream signalling pathways. Five-day proliferation assays were carried out in the presence or absence of VEGF. IHC analysis of NSCLC demonstrated tumour cell VEGFR2 expression in 20% of samples. Immunoblot analysis showed expression of VEGFR2 protein in 3/8 NSCLC cell lines that correlated with VEGFR2 mRNA expression levels. VEGF-dependent VEGFR2 activation was apparent in NSCLC cells, and was associated with increased tumor cell proliferation. Cediranib treatment or siRNA against VEGFR2 inhibited VEGF-dependent increases in cell proliferation. Inhibition of VEGFR2 tyrosine kinase activity using cediranib was more effective than inhibition of AKT (MK2206) or MEK (AZD6244) for overcoming VEGFR2-driven cell proliferation. VEGF treatment did not affect cell survival following treatment with radiation, cisplatin, docetaxel or gemcitabine. Our data suggest that a subset of NSCLC tumour cells express functional VEGFR2 which can act to promote VEGF-dependent tumour cell growth. In this tumour subset, therapies targeting VEGFR2 signalling, such as cediranib, have the potential to inhibit both tumour cell proliferation and angiogenesis.

View Figures

View References

1	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 9(Suppl 1): 2–10. 2004. View Article : Google Scholar : PubMed/NCBI
3	Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
4	Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
5	Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol. 28:2137–2143. 2010. View Article : Google Scholar : PubMed/NCBI
6	Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, et al: Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther. 10:861–873. 2011. View Article : Google Scholar : PubMed/NCBI
7	Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, et al: Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 63:8890–8898. 2003.PubMed/NCBI
8	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
9	Cabebe E and Wakelee H: Role of anti-angiogenesis agents in treating NSCLC: Focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 8:15–27. 2007. View Article : Google Scholar : PubMed/NCBI
10	Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, et al: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 24:769–777. 2006. View Article : Google Scholar : PubMed/NCBI
11	Morelli MP, Brown AM, Pitts TM, Tentler JJ, Ciardiello F, Ryan A, Jürgensmeier JM and Eckhardt SG: Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): Effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther. 8:2546–2558. 2009. View Article : Google Scholar : PubMed/NCBI
12	Molhoek KR, Erdag G, Rasamny JK, Murphy C, Deacon D, Patterson JW, Slingluff CL Jr and Brautigan DL: VEGFR-2 expression in human melanoma: revised assessment. Int J Cancer. 129:2807–2815. 2011. View Article : Google Scholar : PubMed/NCBI
13	Adamcic U, Skowronski K, Peters C, Morrison J and Coomber BL: The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. Neoplasia. 14:612–623. 2012. View Article : Google Scholar : PubMed/NCBI
14	Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT and Bremnes RM: Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res. 13:6649–6657. 2007. View Article : Google Scholar : PubMed/NCBI
15	Bonnesen B, Pappot H, Holmstav J and Skov BG: Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis. Lung Cancer. 66:314–318. 2009. View Article : Google Scholar : PubMed/NCBI
16	An SJ, Nie Q, Chen ZH, Lin QX, Wang Z, Xie Z, Chen SL, Huang Y, Zhang AY, Yan JF, et al: KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer. J Cancer Res Clin Oncol. 133:635–642. 2007. View Article : Google Scholar : PubMed/NCBI
17	Matsuyama W, Hashiguchi T, Mizoguchi A, Iwami F, Kawabata M, Arimura K and Osame M: Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest. 118:948–951. 2000. View Article : Google Scholar : PubMed/NCBI
18	Masood R, Cai J, Zheng T, Smith DL, Hinton DR and Gill PS: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 98:1904–1913. 2001. View Article : Google Scholar : PubMed/NCBI
19	Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T and Ichinose Y: Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer. 53:91–96. 2006. View Article : Google Scholar : PubMed/NCBI
20	Bokobza SM, Jiang Y, Weber AM, Devery AM and Ryan AJ: Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 88:947–954. 2014. View Article : Google Scholar : PubMed/NCBI
21	Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla C, et al: Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol. 30:1129–1136. 2012. View Article : Google Scholar : PubMed/NCBI
22	Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, et al: Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res. 16:3548–3561. 2010. View Article : Google Scholar : PubMed/NCBI
23	Holzer TR, Fulford AD, Nedderman DM, Umberger TS, Hozak RR, Joshi A, Melemed SA, Benjamin LE, Plowman GD, Schade AE, et al: Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung. PLoS One. 8:e802922013. View Article : Google Scholar : PubMed/NCBI
24	Zeng H, Dvorak HF and Mukhopadhyay D: Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phos-phatidylinositol 3-kinase-dependent pathways. J Biol Chem. 276:26969–26979. 2001. View Article : Google Scholar : PubMed/NCBI
25	Favot L, Keravis T, Holl V, Le Bec A and Lugnier C: VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost. 90:334–343. 2003.PubMed/NCBI
26	Prior BM, Yang HT and Terjung RL: What makes vessels grow with exercise training? J Appl Physiol 1985. 97:1119–1128. 2004. View Article : Google Scholar : PubMed/NCBI
27	Matsumori Y, Yano S, Goto H, Nakataki E, Wedge SR, Ryan AJ and Sone S: ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res. 16:15–26. 2006.PubMed/NCBI
28	Liang Y, Brekken RA and Hyder SM: Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer. 13:905–919. 2006. View Article : Google Scholar : PubMed/NCBI
29	Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E and Kikuchi K: Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer. 46:11–19. 2004. View Article : Google Scholar : PubMed/NCBI
30	Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, et al: Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther. 6:471–483. 2007. View Article : Google Scholar : PubMed/NCBI
31	Carrillo de Santa Pau E, Arias FC, Caso Peláez E, Muñoz Molina GM, Sánchez Hernández I, Muguruza Trueba I, Moreno Balsalobre R, Sacristán López S, Gómez Pinillos A and del Val Toledo Lobo M: Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer. 115:1701–1712. 2009. View Article : Google Scholar : PubMed/NCBI
32	Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 39:469–478. 2006. View Article : Google Scholar : PubMed/NCBI
33	Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD and Thorpe PE: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 60:5117–5124. 2000.PubMed/NCBI
34	Abid MR, Guo S, Minami T, Spokes KC, Ueki K, Skurk C, Walsh K and Aird WC: Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler Thromb Vasc Biol. 24:294–300. 2004. View Article : Google Scholar
35	Silva SR, Bowen KA, Rychahou PG, Jackson LN, Weiss HL, Lee EY, Townsend CM Jr and Evers BM: VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer. 128:1045–1056. 2011. View Article : Google Scholar
36	Adham SA, Sher I and Coomber BL: Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells. Lab Invest. 90:709–723. 2010. View Article : Google Scholar : PubMed/NCBI
37	Datta SR, Brunet A and Greenberg ME: Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927. 1999. View Article : Google Scholar : PubMed/NCBI
38	Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, et al: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 106:511–521. 2000. View Article : Google Scholar : PubMed/NCBI
39	Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J and Reck M: Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 27:4274–4280. 2009. View Article : Google Scholar : PubMed/NCBI
40	Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, et al: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 26:650–656. 2008. View Article : Google Scholar : PubMed/NCBI
41	Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, et al: Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: Results from a phase II study. J Clin Oncol. 27:3836–3841. 2009. View Article : Google Scholar : PubMed/NCBI
42	Chatterjee S, Heukamp LC, Siobal M, Schöttle J, Wieczorek C, Peifer M, Frasca D, Koker M, König K, Meder L, et al: Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 123:1732–1740. 2013. View Article : Google Scholar : PubMed/NCBI